Visit main University website

University of Sydney logo

Find MND Biomarker

University of Sydney logo

Find MND Biomarker

↑

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI:

The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids 

DOI: https://doi.org/10.1002/ana.27300

Contact: For help contact [email protected]
Sort by:
Total Records Found: 4574, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
CBLB Q13191 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CAT P04040 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CAT P04040 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CAT P04040 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CAST H0Y944 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CAST P20810 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CAST P20810 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
CASP14 P31944 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CASKIN1 Q8WXD9 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CASC4 Q6P4E1 Trautwig et al. 2025 Sporadic ALS Control CSF Down 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
CARTPT Q16568 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CARTPT Q16568 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
CARTPT Q16568 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CARS1 P49589 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CARNS1 A5YM72 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CARHSP1 H3BTK3 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CAPZB B1AK87 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CAPZA2 P47755 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CAPZA2 C9JUG7 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CAPZA1 P52907 Zubiri et al. 2018 ALS fast (late stage) ALS slow (late stage) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CAPZA1 P52907 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CAPZA1 P52907 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CAPZA1 P52907 Zubiri et al. 2018 Late ALS (ALS fast cohort) Early ALS (ALS fast cohort) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CAPZA1 P52907 Zubiri et al. 2018 Late ALS (ALS slow cohort) Early ALS (ALS slow cohort) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CAPZA1 P52907 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
CAPZA1 P52907 Filareti et al. 2017 Late ALS Early ALS PBMCs Down 16 Early-ALS, 16 Late-ALS N/A 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS) N/A
CAPS K7EL21 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CAPRIN1 A0A087X082 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CAPNS1 P04632 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CAPNS1 A0A0C4DGQ5 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CAPN5 A0A087X0C8 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CAPG P40121 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CAPG P40121 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
CAPG P40121 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CAPG P40121 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
CAP2 P40123 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CAP1 Q01518 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CAP1 Q01518 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CAP1 Q01518 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CAP1 Q01518 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CANX P27824 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CANX P27824 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CANX P27824 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CANX P27824 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CANT1 Q8WVQ1 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CAND1 Q86VP6 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CAMKV Q8NCB2 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CAMKK1 Q8N5S9 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CAMK2G Q13555 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CAMK2G Q13555 Umoh et al. 2018 ALS Control Frontal cortex Down 19 ALS, 10 control 55 59 10.6
CAMK2B Q13554 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CAMK2B Q13554 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
CAMK2B Q13554 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CAMK2A Q9UQM7 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CAMK2A Q9UQM7 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CAMK2A Q9UQM7 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CAMK2A Q9UQM7 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Down 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
CAMK2A Q9UQM7 Vu et al. 2023 ALS fast ALS slow CSF Down 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
CAMK1D Q8IU85 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CALY Q9NYX4 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CALY Q9NYX4 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CALU O43852 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CALU O43852 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CALR P27797 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CALR P27797 Filareti et al. 2017 Late ALS Early ALS PBMCs Up 16 Early-ALS, 16 Late-ALS N/A 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS) N/A
CALR P27797 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CALR P27797 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CALM3 P62158 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CALM3 P62158 Zubiri et al. 2018 ALS fast (late stage) ALS slow (late stage) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CALM3 P62158 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CALM3 P62158 Zubiri et al. 2018 Late ALS (ALS fast cohort) Early ALS (ALS fast cohort) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CALM3 P62158 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CALM1 P0DP23 Englen-Lee et al. 2017 ALS Control Spinal cord (PH & AH) Down 10 ALS, 10 control 57.6 ± 10.9 62.6 ± 10.6 N/A
CALM1 P0DP23 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CALD1 Q05682 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CALCB P10092 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CALCA P06881 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CALCA P06881 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
CALCA P06881 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CALB2 P22676 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CALB2 P22676 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CALB2 P22676 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CADPS Q9ULU8 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CADPS Q9ULU8 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CADM4 Q8NFZ8 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CADM4 Q8NFZ8 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CADM3 Q8N126 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
CADM1 Q9BY67 Bereman et al. 2018 ALS Control CSF Down 33 ALS, 30 control N/A N/A N/A
CACYBP Q9HB71 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
CACNG8 Q8WXS5 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CACNA2D3 Q8IZS8 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CACNA2D2 Q9NY47 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CACNA2D2 Q9NY47 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CACNA2D1 P54289 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CACNA2D1 P54289 Bereman et al. 2018 ALS Control CSF Down 33 ALS, 30 control N/A N/A N/A
CACHD1 Q5VU97 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CACHD1 Q5VU97 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CA4 P22748 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CA4 P22748 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CA3 P07451 Chia et al. 2025 ALS Control Plasma Up 231 ALS, 384 control (214 healthy control, 170 other neurological conditions) N/A 65.1 ± 10.8 N/A